Crossmark Global Holdings’s GSK GSK Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $2.14M | Buy |
40,875
+2,387
| +6% | +$126K | 0.03% | 444 |
|
|
2026
Q1 | $2.12M | Sell |
38,488
-3,687
| -9% | -$200K | 0.03% | 423 |
|
|
2025
Q4 | $2.07M | Buy |
42,175
+944
| +2% | +$44K | 0.03% | 428 |
|
|
2025
Q3 | $1.78M | Buy |
41,231
+1,546
| +4% | +$60.4K | 0.03% | 481 |
|
|
2025
Q2 | $1.52M | Hold |
39,685
| – | – | 0.02% | 501 |
|
|
2025
Q1 | $1.54M | Buy |
39,685
+125
| +0.3% | +$4.58K | 0.03% | 485 |
|
|
2024
Q4 | $1.34M | Hold |
39,560
| – | – | 0.02% | 494 |
|
|
2024
Q3 | $1.62M | Buy |
39,560
+9,017
| +30% | +$369K | 0.03% | 462 |
|
|
2024
Q2 | $1.18M | Buy |
30,543
+803
| +3% | +$33.8K | 0.02% | 542 |
|
|
2024
Q1 | $1.27M | Sell |
29,740
-1,256
| -4% | -$51.8K | 0.02% | 540 |
|
|
2023
Q4 | $1.15M | Buy |
30,996
+887
| +3% | +$31.8K | 0.02% | 560 |
|
|
2023
Q3 | $1.12M | Buy |
30,109
+90
| +0.3% | +$3.19K | 0.03% | 543 |
|
|
2023
Q2 | $1.06M | Buy |
30,019
+2,200
| +8% | +$78.9K | 0.02% | 577 |
|
|
2023
Q1 | $990K | Buy |
27,819
+282
| +1% | +$9.87K | 0.02% | 586 |
|
|
2022
Q4 | $967K | Buy |
27,537
+348
| +1% | +$11.6K | 0.02% | 582 |
|
|
2022
Q3 | $800K | Buy |
27,189
+3,445
| +15% | +$131K | 0.02% | 610 |
|
|
2022
Q2 | $1.29M | Sell |
23,744
-576
| -2% | -$31.8K | 0.03% | 499 |
|
|
2022
Q1 | $1.32M | Buy |
24,320
+2,096
| +9% | +$114K | 0.03% | 534 |
|
|
2021
Q4 | $1.23M | Sell |
22,224
-8
| -0% | -$416 | 0.03% | 565 |
|
|
2021
Q3 | $1.06M | Buy |
22,232
+232
| +1% | +$11.7K | 0.02% | 592 |
|
|
2021
Q2 | $1.09M | Sell |
22,000
-1,024
| -4% | -$49.2K | 0.03% | 580 |
|
|
2021
Q1 | $1.03M | Sell |
23,024
-9,387
| -29% | -$426K | 0.03% | 585 |
|
|
2020
Q4 | $1.49M | Buy |
32,411
+421
| +1% | +$19.3K | 0.04% | 453 |
|
|
2020
Q3 | $1.5M | Buy |
31,990
+960
| +3% | +$48.1K | 0.04% | 417 |
|
|
2020
Q2 | $1.58M | Sell |
31,030
-669
| -2% | -$34.3K | 0.05% | 395 |
|
|
2020
Q1 | $1.5M | Buy |
31,699
+1,744
| +6% | +$93K | 0.05% | 358 |
|
|
2019
Q4 | $1.76M | Buy |
29,955
+2,288
| +8% | +$127K | 0.05% | 407 |
|
|
2019
Q3 | $1.48M | Sell |
27,667
-22,024
| -44% | -$1.13M | 0.04% | 444 |
|
|
2019
Q2 | $2.49M | Buy |
49,691
+1,032
| +2% | +$51.8K | 0.07% | 313 |
|
|
2019
Q1 | $2.54M | Buy |
48,659
+128
| +0.3% | +$6.4K | 0.07% | 303 |
|
|
2018
Q4 | $2.32M | Sell |
48,531
-368
| -0.8% | -$18.1K | 0.07% | 306 |
|
|
2018
Q3 | $2.46M | Buy |
48,899
+19,584
| +67% | +$995K | 0.06% | 347 |
|
|
2018
Q2 | $1.48M | Sell |
29,315
-48,040
| -62% | -$2.42M | 0.04% | 478 |
|
|
2018
Q1 | $3.78M | Sell |
77,355
-20,707
| -21% | -$964K | 0.1% | 255 |
|
|
2017
Q4 | $4.35M | Sell |
98,062
-384
| -0.4% | -$17.7K | 0.1% | 237 |
|
|
2017
Q3 | $5M | Buy |
+98,446
| New | +$4.99M | 0.13% | 198 |
|
|
2016
Q3 | $5M | Buy |
+98,446
| New | +$5.4M | 0.13% | 198 |
|
Other funds holding GSK
JEST
Crossmark Global Holdings's GSK Position: Q2 2026 in Review
Crossmark Global Holdings increased its GSK (GSK) stake by 6.2% in Q2 2026, buying an estimated $126K and bringing the position to 40,875 shares worth $2.14M. The position accounts for 0.03% of the portfolio, ranked #444.
Crossmark Global Holdings first reported a position in GSK in Q3 2016 and has held it in 37 quarters since. The position peaked at $5M in Q3 2017. 1,037 funds tracked by Wall St. Rank hold GSK as of Q2 2026.
- Crossmark Global Holdings held 40,875 shares of GSK worth $2.14M as of Q2 2026.
- Crossmark Global Holdings bought 2,387 GSK shares in Q2 2026, an estimated $126K.
- GSK made up 0.03% of Crossmark Global Holdings's portfolio in Q2 2026, its #444 holding.
- Crossmark Global Holdings first reported a position in GSK in Q3 2016 and has held it in 37 quarters since.
- Crossmark Global Holdings's GSK position peaked at $5M in Q3 2017.
- 1,037 funds tracked by Wall St. Rank held GSK as of Q2 2026.
Based on Crossmark Global Holdings's 13F filing for Q2 2026, filed 16 Jul 2026.